fda warning on semaglutide Warns Against Using Compounded FDA warns about semaglutide overdoses,

Efficacy and safety of the dual GIP and GLP-1 receptor agonist tirzepatide for weight loss: a meta-analysis of randomized controlled trials, I Pera Calvi, 2023 How Do Semaglutide and Tirzepatide Compare for Weight Loss

In trials with patients with type 2 diabetes and overweight/obesity, after 16 weeks of treatment with Danuglipron, the high-dose (120 mg twice daily) group showed an average weight loss of 4.2 kg and a reduction in HbA1c levels by 1.2% compared to the placebo group

Ozempic ( semaglutide )is a GLP-1 receptor agonist

Probiotics: Semaglutide alters gut motility, which can disrupt the microbiome

Retrieved from National Institutes of Health